<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818454</url>
  </required_header>
  <id_info>
    <org_study_id>1012.57</org_study_id>
    <secondary_id>57948</secondary_id>
    <nct_id>NCT00818454</nct_id>
  </id_info>
  <brief_title>4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma</brief_title>
  <official_title>A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Study Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma (GINA 2007 Treatment Steps 3-5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI
      with albuterol HFA MDI, the current standard reliever medication in asthma. In the first
      cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC
      MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3)
      COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at
      the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will
      be used for symptom relief as needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-6 Response (Crossover Part of the Study)</measure>
    <time_frame>Test day baseline and test day FEV1 AUC 0-6, after 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under (FEV1 AUC) the Curve from 0 to 6 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak FEV1 Response (Crossover Part of the Study)</measure>
    <time_frame>Test day baseline and test day peak FEV1, after 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in Mini-AQLQ score. Worst score - 1 (most severe), best score - 7 (less severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in ACQ score. Worst score - 6(most severe), best score - 0 (no symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puffs Study Medication Used During Day (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puffs Study Medication Used During Night (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during night</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline in weekly mean of puffs of open-label albuterol used during day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Change from baseline in weekly mean of puffs of open-label albuterol used during night</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-6 Response (Parallel Part of the Study)</measure>
    <time_frame>Test day baseline and test day FEV1 AUC 0-6, after 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under the Curve from 0 to 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Response</measure>
    <time_frame>Test day baseline and test day peak FEV1, after 4 weeks</time_frame>
    <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
  </secondary_outcome>
  <enrollment type="Actual">226</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivent CFC MDI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol HFA MDI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Respimat Combivent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign and date an Informed Consent consistent with International
             Conference on Harmonization Good Clinical Practices (ICH GCP) guidelines and local
             regulations prior to participation in the trial (i.e., prior to any study procedures,
             including washout of any medication) at Visit 1.

          2. Male or female patients greater to or equal to 18 years of age.

          3. Physician diagnosis of moderate-to-severe asthma (GINA Guidelines) existing for &gt;1
             year.

          4. Reversible airway obstruction (more than or equal to 12 % or at least 200 mL
             improvement in FEV1 post bronchodilator after 4 puffs of albuterol HFA MDI).

          5. Pre-bronchodilator clinic measured FEV1 ≤80% of predicted normal value (measured
             greater to or equal to 6 hours of the last use of short acting bronchodilator and
             greater to or equal to 12 hours after the last use of LABA if applicable).

          6. Continuous treatment with inhaled corticosteroids (ICS) with or without long-acting
             beta agonists (LABA) and other controller medication(s) for at least 6 weeks prior to
             screening (GINA 2007 Treatment Steps 3 to 5).

          7. No change in dos or regimen of ICS and LABA or other controller medications (including
             oral corticosteroids [OCS] if applicable), for at least 2 weeks prior to Visit 2.

          8. Use of short acting bronchodilator at least three times a week for symptom relief in
             the 2 weeks prior to Visit 1.

          9. Score of ≥1.5 points on the Asthma Control Questionnaire (ACQ) (see Appendix 10.6).

         10. Able to perform technically acceptable pulmonary function tests at the clinic and peak
             flow measurements with the eDiary/Peak Expiratory Flow Meter.

         11. Able to perform all necessary recordings (symptoms and as needed medication use) in
             the electronic diary, which is a part of the eDiary/Peak Expiratory Flow Meter.

         12. Investigator assessment of patients ability to inhale medication from a metered dose
             inhaler and RESPIMAT inhaler.

        Exclusion Criteria:

          1. Significant disease other than asthma not limited to diagnosis of COPD, such as,
             active tuberculosis, cystic fibrosis, alpha 1 antitrypsin deficiency, clinically
             significant bronchiectasis, interstitial lung disease, allergic bronchopulmonary
             aspergillosis, or constrictive bronchiolitis. A significant disease is defined as a
             disease which, in the opinion of the investigator, may (i) put the patient at risk
             because of participation in the study, or (ii) influence the results of the study, or
             (iii) cause concern regarding the patient ability to participate in the study.

          2. History of thoracotomy with pulmonary resection. Patients with a history of
             thoracotomy for other reasons should be evaluated as per exclusion criterion 1.

          3. History of life-threatening asthma attack.

          4. Worsening of asthma that required treatment with an addition or increase in OCS dose
             (steroid burst) in the 4- week period prior to Visit 2.

          5. Current or ex-smokers who quit &lt;1 year before enrollment. Ex-smokers who quit less
             than 1 year from enrollment must have a cigarette smoking history of less than 10 pack
             years.

             Pack years = Number of cigarettes/day x years of smoking 20

          6. Use of oral beta-adrenergic agents within 4 weeks prior to screening.

          7. Treatment with inhaled ipratropium, ipratropium/albuterol combination, or nasal
             ipratropium within 1week of Visit 2.

          8. Treatment with inhaled tiotropium within 4 weeks of Visit 2.

          9. Known hypersensitivity to anticholinergic drugs, benzalkonium chloride (BAC),
             ethylenediaminetetracetic acid (EDTA) or any other components of the tiotropium
             inhalation solution or MDI.

         10. Known narrow-angle glaucoma.

         11. Clinically relevant abnormal hematology or blood chemistry at screening if the
             abnormality defines a significant disease as defined in exclusion criterion 1.

         12. Recent history (i.e., one year less) of myocardial infarction. Cardiac arrhythmias,
             newly diagnosed arrhythmias and/or any arrhythmia requiring an intervention (i.e.,
             hospitalization, cardio version, pacemaker placement, and automatic implantable
             cardiac defibrillator placement) or a change in drug therapy during the last year.

         13. Hospitalization for cardiac failure during the past year.

         14. Malignancy for which the patient has undergone resection, radiation therapy or
             chemotherapy within the last five years, with the exception of treated basal cell
             carcinoma.

         15. Unwillingness or inability to use a highly effective method of birth control by women
             of childbearing potential. Highly effective methods of birth control are defined as
             those which result in a low failure rate (i.e., less than 1% per year) when used
             consistently and correctly such as implants, injectables, combined oral
             contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised
             partner. Barrier methods of contraception are accepted if condom or occlusive cap is
             used together with spermicides (e.g., foam or gel). Female patients will be considered
             to be of childbearing potential unless surgically sterilized by hysterectomy or
             bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years.

         16. Pregnancy or nursing.

         17. Any investigational drug taken within 30 days or six half-lives (whichever is greater)
             prior to Visit 2.

         18. Previous randomization in this study or current participation in another study.

         19. Symptomatic prostate hypertrophy or bladder neck obstruction. Patients with
             symptomatically controlled prostate hypertrophy on medications may be included and
             should continue their medications.

         20. Use of monoamine oxidase inhibitors or tricyclic antidepressants. Examples include but
             are not limited to the following for monoamine oxidase inhibitors nardil, parnate,
             marplan and for tricyclic antidepressants: amitriptyline, norpramine, and pamelor.

         21. History of and/or active alcohol or drug abuse.

         22. Patient who have been treated with beta-blocker medication during the screening of the
             study. Topical cardio-selective beta-blocker eye medications for treatment of acute
             angle glaucoma are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1012.57.121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.147 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.150 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.57.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <results_first_submitted>September 21, 2010</results_first_submitted>
  <results_first_submitted_qc>October 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2010</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Crossover Part of the Study (Treatment Period 1)
Crossover Part of the Study (Washout Period of 1 Week)
Crossover Part of the Study (Treatment Period 2)
Parallel Part of the Study Following Second Randomization (Treatment Period 3)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Albuterol HFA First, Then Combivent CFC</title>
          <description>Albuterol Hydrofluoroalkene, Combivent Chlorofluorocarbon</description>
        </group>
        <group group_id="P2">
          <title>Combivent CFC First, Then Albuterol HFA</title>
          <description>Combivent Chlorofluorocarbon, Albuterol Hydrofluoroalkene</description>
        </group>
        <group group_id="P3">
          <title>Placebo Respimat</title>
          <description>Placebo Respimat (matching Combivent Respimat)</description>
        </group>
        <group group_id="P4">
          <title>Combivent Respimat</title>
          <description>Combivent Respimat (contains the effective dose of albuterol)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 1 Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Participants randomized to crossover part at randomization 1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Amer. Ind./Alaska Nat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African Amer.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacif. Isle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>Kilograms per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - possible interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.9" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-6 Response (Crossover Part of the Study)</title>
        <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under (FEV1 AUC) the Curve from 0 to 6 hours.</description>
        <time_frame>Test day baseline and test day FEV1 AUC 0-6, after 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 Response (Crossover Part of the Study)</title>
          <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under (FEV1 AUC) the Curve from 0 to 6 hours.</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.026"/>
                    <measurement group_id="O2" value="0.252" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak FEV1 Response (Crossover Part of the Study)</title>
        <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
        <time_frame>Test day baseline and test day peak FEV1, after 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response (Crossover Part of the Study)</title>
          <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" spread="0.031"/>
                    <measurement group_id="O2" value="0.434" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)</title>
        <description>Change from baseline after 4 weeks in Mini-AQLQ score. Worst score - 1 (most severe), best score - 7 (less severe)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)</title>
          <description>Change from baseline after 4 weeks in Mini-AQLQ score. Worst score - 1 (most severe), best score - 7 (less severe)</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Scores on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" spread="0.05"/>
                    <measurement group_id="O2" value="0.220" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (Crossover Part of the Study)</title>
        <description>Change from baseline after 4 weeks in ACQ score. Worst score - 6(most severe), best score - 0 (no symptoms)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (Crossover Part of the Study)</title>
          <description>Change from baseline after 4 weeks in ACQ score. Worst score - 6(most severe), best score - 0 (no symptoms)</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Scores on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.04"/>
                    <measurement group_id="O2" value="-0.25" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8278</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Puffs Study Medication Used During Day (Crossover Part of the Study)</title>
        <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during day</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Puffs Study Medication Used During Day (Crossover Part of the Study)</title>
          <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during day</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.07"/>
                    <measurement group_id="O2" value="-0.53" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5098</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Puffs Study Medication Used During Night (Crossover Part of the Study)</title>
        <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during night</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Puffs Study Medication Used During Night (Crossover Part of the Study)</title>
          <description>Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during night</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.05"/>
                    <measurement group_id="O2" value="-0.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6591</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)</title>
        <description>Change from baseline in weekly mean of puffs of open-label albuterol used during day</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)</title>
          <description>Change from baseline in weekly mean of puffs of open-label albuterol used during day</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="0.05"/>
                    <measurement group_id="O2" value="-2.28" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3631</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)</title>
        <description>Change from baseline in weekly mean of puffs of open-label albuterol used during night</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol HFA</title>
            <description>Albuterol Hydrofluoroalkene</description>
          </group>
          <group group_id="O2">
            <title>Combivent CFC</title>
            <description>Combivent Chlorofluorocarbon</description>
          </group>
        </group_list>
        <measure>
          <title>Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)</title>
          <description>Change from baseline in weekly mean of puffs of open-label albuterol used during night</description>
          <population>Full analysis set 1 (FAS1) consisted of all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had non-missing Visit 3 baseline values and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 3.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.02"/>
                    <measurement group_id="O2" value="-0.93" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Enter additional comments here, if non-inferiority or equivalence analysis</non_inferiority_desc>
            <p_value>0.6787</p_value>
            <method>MMRM ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-6 Response (Parallel Part of the Study)</title>
        <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under the Curve from 0 to 6 hours</description>
        <time_frame>Test day baseline and test day FEV1 AUC 0-6, after 4 weeks</time_frame>
        <population>These analyses were done on FAS2. FAS2 is all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had a non-missing Visit 7 baseline value and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat (matching Combivent Respimat)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Respimat</title>
            <description>Combivent Respimat (contains the effective dose of albuterol)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-6 Response (Parallel Part of the Study)</title>
          <description>Change from baseline after 4 weeks in Forced Expiratory Volume Area Under the Curve from 0 to 6 hours</description>
          <population>These analyses were done on FAS2. FAS2 is all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had a non-missing Visit 7 baseline value and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 7.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" spread="0.046"/>
                    <measurement group_id="O2" value="0.236" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, period, week, and treatment by week interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Response</title>
        <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
        <time_frame>Test day baseline and test day peak FEV1, after 4 weeks</time_frame>
        <population>These analyses were done on FAS2. FAS2 is all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had a non-missing Visit 7 baseline value and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Placebo Respimat (matching Combivent Respimat)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Respimat</title>
            <description>Combivent Respimat (contains the effective dose of albuterol)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Response</title>
          <description>Change from baseline after 4 weeks in peak Forced Expiratory Volume response</description>
          <population>These analyses were done on FAS2. FAS2 is all patients who were dispensed study medication, were documented to have taken at least one dose of investigational treatment, and had a non-missing Visit 7 baseline value and non-missing responses for both peak FEV1 and FEV1 AUC0-6 at Visit 7.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" spread="0.053"/>
                    <measurement group_id="O2" value="0.412" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, period, week, and treatment by week interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 days (Treatment phase 1) + 29 days (Treatment phase 2) + 29 days (Treatment phase 3)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Albuterol HFA First, Then Combivent CFC</title>
          <description>Albuterol Hydrofluoroalkene, Combivent Chlorofluorocarbon</description>
        </group>
        <group group_id="E2">
          <title>Combivent CFC First, Then Albuterol HFA</title>
          <description>Combivent Chlorofluorocarbon, Albuterol Hydrofluoroalkene</description>
        </group>
        <group group_id="E3">
          <title>Placebo Respimat</title>
          <description>Placebo Respimat (matching Combivent Respimat)</description>
        </group>
        <group group_id="E4">
          <title>Combivent Respimat</title>
          <description>Combivent Respimat (contains the effective dose of albuterol)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

